In the past decade, G protein-coupled receptors have emerged as drug targets, and their physiological and pathological effects have been extensively studied. Among these receptors, GPR119 is expressed in multiple organs, including the liver. It can be activated by a variety of endogenous and exogenous ligands. After GPR119 is activated, the cell secretes a variety of incretins, including glucagon-like peptide-1 and glucagon-like peptide-2, which may attenuate the metabolic dysfunction associated with fatty liver disease, including improving glucose and lipid metabolism, inhibiting inflammation, reducing appetite, and regulating the intestinal microbial system. GPR119 has been a potential therapeutic target for diabetes mellitus type 2 for many years, but its role in metabolic dysfunction associated fatty liver disease deserves further attention. In this review, we discuss relevant research and current progress in the physiology and pharmacology of the GPR119/incretin axis and speculate on the potential therapeutic role of this axis in metabolic dysfunction associated with fatty liver disease, which provides guidance for transforming experimental research into clinical applications.

中文翻译：

---

靶向 GPR119/肠促胰岛素轴：代谢相关性脂肪肝疾病的有希望的新疗法

在过去的十年中，G蛋白偶联受体作为药物靶点出现，其生理和病理作用得到了广泛的研究。在这些受体中，GPR119 在包括肝脏在内的多个器官中表达。它可以被多种内源性和外源性配体激活。GPR119被激活后，细胞分泌多种肠促胰岛素，包括胰高血糖素样肽-1和胰高血糖素样肽-2，可减轻与脂肪肝相关的代谢功能障碍，包括改善糖脂代谢、抑制炎症、降低食欲，调节肠道微生物系统。GPR119多年来一直是2型糖尿病的潜在治疗靶点，但其在代谢功能障碍相关脂肪肝疾病中的作用值得进一步关注。